This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 10, 2008
Last updated: June 25, 2009
Last verified: June 2009
The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.

Condition Intervention Phase
Healthy Volunteer Drug: AZD6280 Drug: Lorazepam Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD6280 on Sedation, Cognition and EEG in Comparison With Lorazepam in Healthy Male Volunteers

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluation of the pharmacodynamic effects of AZD6280 by central nervous system function tests [ Time Frame: Test batteries will be performed at specified times both before and following study drug administration ]

Secondary Outcome Measures:
  • Evaluation and characterization of the pharmacokinetics of AZD6280 [ Time Frame: Blood samples will be taken during the study. ]

Enrollment: 17
Study Start Date: September 2008
Study Completion Date: December 2008
Arms Assigned Interventions
Experimental: 1 Drug: AZD6280
10mg Capsule, oral, single-dose
Experimental: 2 Drug: AZD6280
40mg Capsule, oral, single-dose
Active Comparator: 3 Drug: Lorazepam
2mg tablet, oral single-dose
Other Name: Ativan
Placebo Comparator: 4 Drug: Placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female subjects aged 18 to 55 years (inclusive) on Day 1.
  • Female subjects must be of non-child bearing potential.

Exclusion Criteria:

  • Clinically significant illness within 2 weeks before the study start.
  • Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
  • Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
  • Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00750802

Research Site
Leiden, Netherlands
Sponsors and Collaborators
  More Information

Responsible Party: Mark Smith, MD, MSD, Emerging Psychiatry, AstraZeneca Pharmaceuticals Identifier: NCT00750802     History of Changes
Other Study ID Numbers: D0850C00014
Eudract # 2008-001757-17
Study First Received: September 10, 2008
Last Updated: June 25, 2009

Keywords provided by AstraZeneca:
Phase I

Additional relevant MeSH terms:
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2017